AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models.

Area of Science:

• Muscle biology
• Gene therapy
• Neuromuscular disorders

Background:

• Dysferlinopathies are genetic muscle disorders caused by mutations in the dysferlin gene, leading to progressive muscle weakness and degeneration.
• Current treatments are limited, necessitating novel therapeutic strategies like gene therapy.

Purpose of the Study:

• To demonstrate the efficacy and safety of a dual vector gene therapy approach for restoring dysferlin expression.
• To overcome the packaging limitations of adeno-associated virus (AAV) for delivering the large dysferlin gene.

Main Methods:

• A dual vector system (AAV.DYSF.DV) utilizing AAV serotype rh.74 was developed to deliver dysferlin cDNA.
• Intramuscular and vascular delivery routes were compared in dysferlin-deficient mice and nonhuman primates.

Main Results:

• High levels of dysferlin expression were observed in all treated muscle groups.
• Functional recovery, including membrane repair and diaphragm specific force, reached wild-type levels.
• Nonhuman primates showed strong dysferlin expression without adverse safety events.

Conclusions:

• The dual vector gene therapy approach effectively restored dysferlin expression and muscle function in preclinical models.
• The treatment demonstrated a favorable safety profile, with no observed toxicity or immune response.
• This study provides proof of principle for translating this gene therapy to patients with dysferlinopathies.